X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

WUXI BIOLOGICS and PRIMA sign MOU and Announce Strategic Development and Manufacturing Partnership

Yuvraj_pawp by Yuvraj_pawp
23rd November 2016
in Americas, Projects

Prima BioMed Ltd and WuXi Biologics ,a WuXi AppTec group company, and a leading open-access R&D capability and technology platform company dedicated to expedite global biologics development, announced that a non-binding MOU was signed to form a strategic biologics development and manufacturing partnership.

Under the partnership, WuXi Biologics will be the exclusive clinical and commercial manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of mainland China, Macau, Taiwan and Hong Kong where rights are retained by Prima’s development partner in China, Eddingpharm. WuXi Biologics will also be Prima’s preferred partner to manufacture potential new products.


IMP321, a first-in-class soluble LAG-3 Ig fusion protein, is an APC activator, boosting T cell 
responses for cancer chemo-immunotherapy and in other combinations and is in Phase II trials in Europe. In 2013, Eddingpharm obtained the rights to develop, manufacture and commercialize IMP321 in the Greater China region.


CEO of Prima BioMed, Marc Voigt said “Securing the future supply of IMP321 is a key component 
of our commercial development strategy. WuXi Biologics have consistently delivered the highest quality materials for our clinical trials. This MOU further strengthens our important strategic partnership.”


“We are honoured to play a critical role to enable small and mid-size companies to realize 
commercialization via WuXi’s innovative biomanufacturing network based on state-of-the-art disposable manufacturing technology”, said Dr. Chris Chen, CEO of WuXi Biologics, “We are committed to producing the highest quality biologics to ensure robust global supply to patients
worldwide.”


About Prima BioMed

Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.


Prima’s current lead product is IMP321, based on the LAG-3 immune control mechanism which 
plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

 

Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au

 

Australia Investor/Media:
Mr Matthew Gregorowski, Citadel-MAGNUS
+61 (2) 8234 0100;
mgregorowski@citadelmagnus.com


U.S. Investors:

Matthew Beck, The Trout Group LLC
+1 (646) 378-2933;
mbeck@troutgroup.com

Tags: America
Previous Post

Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass.

Next Post

The European Commission Grants VAL001 Orphan Drug Designation for the Treatment of Diffuse Large B-cell Lymphoma

Related Posts

Cellbox Solutions Establishes Subsidiary in the USA
Americas

Cellbox Solutions Establishes Subsidiary in the USA

24th September 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Americas

US Allows Johnson & Johnson Covid Vaccination To Resume

26th April 2021
POINT Biopharma to Launch First US Manufacturing Facility in Indiana
Americas

POINT Biopharma to Launch First US Manufacturing Facility in Indiana

5th June 2020
AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand
Americas

AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand

5th May 2020
Lilly to invest $400m to boost manufacturing capacity in US
Americas

Lilly to invest $400m to boost manufacturing capacity in US

26th November 2019
AI-based drug development
Americas

Janssen partners with nference for AI-based drug development

15th June 2019
Next Post

The European Commission Grants VAL001 Orphan Drug Designation for the Treatment of Diffuse Large B-cell Lymphoma

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In